Psychoneuroimmunology in Context of Comprehensive Breast Cancer Treatment

Česká verze

Authors: K. Skřivanová ¹; J. Gregor ²; M. Bendová ³; D. Brančíková ^1,4; N. Elfmarkova ^1,5; T. Sverak ⁶; H. Peterkova ^1,7; L. Dušek ²
Authors place of work: Ústav psychologie a psychosomatiky, LF MU, Brno ¹; Institut biostatistiky a analýz, LF a PřF MU, Brno ²; Gynekologicko‑porodnická klinika LF MU a FN Brno ³; Interní hematologická a onkologická klinika LF MU a FN Brno ⁴; CEITEC – Středoevropský technologický institut, MU, Brno ⁵; Psychiatrická klinika LF MU a FN Brno7 Katedra psychologie FF UP v Olomouci ⁶
Published in the journal: Klin Onkol 2014; 27(2): 103-107
Category: Přehledy

Summary

Background:
Numerous studies have proven a relationship between stress and cancer progression or recurrence, and on the other hand, positive effects of psychological and social support and interventions on cancer patients’ quality of life.

Purpose:
This review article aims to provide an overview of recent studies that dealt with effects of psychosocial interventions on health and psychological state of breast cancer patients, from cellular and immune response over coping skills to overall survival.

Conclusion:
Both short- and long-term studies have proven positive effects of psychosocial interventions on levels of stress hormones, cellular (immune) response and general patients’ quality of life. On the other hand, findings on overall survival are contradictory and cannot provide unambiguous conclusions.

Key words:
psychoneuroimmunology – breast cancer – coping behavior – stress – adaptation

Zdroje

1. Ader R, Cohen N. Behaviorally conditioned immunosupression. Psychosom Med 1975; 37(4): 4333– 4340.

2. Wilhelm Z (ed.). Stručný přehled fyziologie člověka pro bakalářské studijní programy. Brno: Masarykova univerzita 2003.

3. Kiecolt‑ Glaser JK, Glaser R. Methodological issues in behavior immunology research with humans. Brain Behav Immun 1988; 2(1): 67– 78.

4. Hořejší V, Bartůňková J (eds). Základy imunologie. 2. vyd. Praha: Triton 2002.

5. Bovbjerg DH, Valdimarsdottir HB. Psychoneuroimmunology: implications for psycho‑ oncology. In: Holland JC (ed.). Psycho‑ oncology. New York: Oxford University Press 1998: 125– 134.

6. Šolcová I, Kebza V. Psychoneuroimunologie a zvládání stresu. Čs. psychologie 1998; 42(1): 32– 41.

7. Zorrilla EP, Luborsky L, McKay JR et al. The relationship of depression and stressors to immunological assays: a meta‑analytic review. Brain Behav Immun 2001; 15(3): 199– 226.

8. Kiecolt‑ Glaser JK, Robles TF, Heffner KL et al. Psycho‑ oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol 2002; 13 (Suppl 4): 165– 169.

9. Green McDonald P, O‘Connell M, Lutgendorf SK. Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations. Brain Behav Immun 2013; 30 (Suppl): S1– S9.

10. Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun 2013; 30 (Suppl): S41– S47.

11. Lutgendorf SK, Sood AK, Anderson B et al. Social support, distress, and natural killer cell activity in ovarian cancer patients. J Clin Oncol 2005; 23(28): 7106– 7113.

12. Nelson EL, Wenzel LB, Osann K et al. Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial corrected. Clin Cancer Res 2008; 14(7): 2111– 2118.

13. Bendová M, Honzák R, Tesařík Z. Psychotherapy in patients with ovarian carcinoma. 3rd World Congress of Psycho‑ Oncology. Psycho‑ Oncology 1996; 5 (Suppl 3): 30.

14. Cohen L, Cole SW, Sood AK et al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 2012; 7(8): e42324.

15. Sephton SE, Lush E, Dedert EA et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun 2013; 30 (Suppl): S163– S170.

16. Starkweather AR, Sherwood P, Lyon DE et al. A biobehavioral perspective on depressive symptoms in patients with cerebral astrocytoma. J Neurosci Nurs 2011; 43(1): 17– 28.

17. Lamkin DM, Sloan EK, Patel AJ et al. Chronic stress enhances progression of acute lymphoblastic leukemia via β‑adrenergic signaling. Brain Behav Immun 2012; 26(4): 635– 641.

18. Andersen BL, Farrar WB, Golden‑ Kreutz D et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998; 90(1): 30– 36.

19. Dedert E, Lush E, Chagpar A et al. Stress, coping, and circadian disruption among women awaiting breast cancer surgery. Ann Behav Med 2012; 44(1): 10– 20.

20. Andersen BL, Yang HC, Farrar WB et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008; 113(12): 3450– 3458.

21. Andersen BL, Farrar WB, Golden‑ Kreutz DM et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004; 22(17): 3570– 3580.

22. Andersen BL, Shelby RA, Golden‑ Kreutz DM et al. RCT of a psychological intervention for patients with cancer: I. Mechanisms of Change. J Consult Clin Psychol 2007; 75(6): 927– 938.

23. Andersen BL, Farrar WB, Golden‑ Kreutz D et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 2007; 21(7): 953– 961.

24. Goodwin PJ, Leszcz M, Ennis M et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001; 345(24): 1719– 1726.

25. Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983; 45(4): 333– 339.

26. Spiegel D, Bloom JR, Kraemer HC et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2(8668): 888– 891.

27. Thornton LM, Andersen BL, Schuler TA et al. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med 2009; 71(7): 715– 724.

28. Antoni MH, Lutgendorf SK, Blomberg B et al. Cognitive‑ behavioral stress management reverses anxiety‑related leukocyte transcriptional dynamics. Biol Psychiatry 2012; 71(4): 366– 372.

29. Antoni MH, Wimberly SR, Lechner SC et al. Reduction of cancer‑ specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry 2006; 163(10): 1791– 1797.

30. Phillips KM, Antoni MH, Lechner SC et al. Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med 2008, 70(9): 1044– 1049.

31. Phillips KM, Antoni MH, Carver CS et al. Stress management skills and reduction in serum cortisol across the year after surgery for non‑metastatic breast cancer. Cogn Ther Res 2011; 35(6): 595– 600.

32. Bower JE, Ganz PA, Irwin MR et al. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol 2011; 29(26): 3517– 3522.

33. Andersen BL, Thornton LM, Shapiro CL et al. Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res 2010; 16(12): 3270– 3278.

34. Thornton LM, Andersen BL, Carson WE 3rd. Immune, endocrine, and behavioral precursors to breast cancer reccurence: a case control analysis. Cancer Immunol Immunother 2008; 57(10): 1471– 1481.

35. Kissane DW, Grabsch B, Clarke DM et al. Supportive‑ expressive group therapy for women with metastatic breast cancer: survival and psychosocial otcome from a randomised controlled trial. Psychooncology 2007; 16(4): 277– 286.

36. Giese‑ Davis J, Collie K, Rancourt KM et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 2011; 29(4): 413– 420.

37. Reich M, Lesur A, Perdrizet‑ Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 2008; 110(1): 9– 17.

38. Hjerl K, Andersen EW, Keiding N et al. Depression as a prognostic factor for breast cancer mortality. Psychosomatics 2003; 44(1): 24– 30.

39. Dušek L, Májek O, Mužík J et al. Vývoj epidemiologie zhoubných nádorů prsu u žen dle nových dat Národního onkologického registru ČR a dalších datových zdrojů. Prakt Gyn 2013; 17(1): 31– 39.

40. Skřivanová K, Brančíková D, Peterková H et al. Projekt Osobnost pacienta jako spoludeterminanta úspěšnosti onkologické léčby, současný stav a výhledy. In: XX. jihočeské onkologické dny. Český Krumlov, 17.– 19. 10. 2013.